La combinaci\u00f3 de dos inhibidors de la prote\u00efna mTOR aconsegueix frenar el creixement del c\u00e0ncer de fetge primari i destruir les c\u00e8l\u00b7lules tumorals, segons un estudi realitzat per investigadors del grup de Metabolisme i C\u00e0ncer de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL). Els resultats de l\u2019estudi s\u2019avancen en l\u2019edici\u00f3 digital de la revista Science Translational Research.<\/p>\n
El c\u00e0ncer de fetge primari o carcinoma hepatocel\u00b7lular \u00e9s el cinqu\u00e8 c\u00e0ncer m\u00e9s com\u00fa i, degut a la seva agressivitat, \u00e9s el tercer m\u00e9s mortal. Afecta mig mili\u00f3 de persones a tot el m\u00f3n. Dos de cada tres casos estan relacionats amb l\u2019alcoholisme cr\u00f2nic, a l\u2019exposici\u00f3 d\u2019agents t\u00f2xics o a la infecci\u00f3 per hepatitis B o C. La tercera part restant est\u00e0 vinculada amb l\u2019esteatohepatitis no alcoh\u00f2lica, una malaltia cada cop m\u00e9s freq\u00fcent, relacionada amb l\u2019obesitat.<\/p>\n
Actualment, l\u2019antitumoral sorafenib \u00e9s el que est\u00e0 oferint millors resultats en pacients, per\u00f2 la seva efectivitat disminueix amb el temps. Per aquest motiu, \u00e9s necessari trobar noves ter\u00e0pies. Un dels candidats m\u00e9s prometedors s\u00f3n els inhibidors de la via de senyalitzaci\u00f3 mTOR, que est\u00e0 hiperactivada en la meitat dels afectats per carcinoma hepatocel\u00b7lular.<\/p>\n
La investigaci\u00f3 coordinada per investigadors de l\u2019IDIBELL van comparar els efectes en ratolins de dos inhibidors de mTOR. El primer era un derivat de la rapamicina, anomenat everolimus (RAD001), que es comercialitza com a immunosupressor i per tractar diversos c\u00e0ncers. L\u2019altre \u00e9s un f\u00e0rmac de nova generaci\u00f3 anomenat BEZ235 que inhibeix mTOR a trav\u00e9s d\u2019una altra via molecular.<\/p>\n
Durant l\u2019estudi, els investigadors van comprovar de manera inesperada, que la combinaci\u00f3 dels dos f\u00e0rmacs tenia efectes m\u00e9s potents que els dos f\u00e0rmacs per separat. L\u2019administraci\u00f3 conjunta de RAD001 i de BEZ235 frena l\u2019expansi\u00f3 del tumor i provoca la l\u2019autodestrucci\u00f3 de les c\u00e8l\u00b7lules tumorals.<\/p>\n
Els resultats de l\u2019estudi han perm\u00e8s iniciar un assaig cl\u00ednic als Estats Units per avaluar l\u2019efic\u00e0cia en humans de la combinaci\u00f3 d\u2019aquests dos inhibidors de mTOR. La coordinadora de l\u2019estudi, Sara Kozma, destaca que \u201cel fet que la rapamicina i els seus derivats ja estiguin aprovats per al tractament d\u2019altres patologies fa pensar que la seva combinaci\u00f3 amb un inhibidor competitiu de l\u2019ATP a trav\u00e9s de la via PI3K\/mTOR, com BEZ235, pot ser una estrat\u00e8gia per accelerar la seva aprovaci\u00f3 per a \u00fas cl\u00ednic\u201d.<\/p>\n
La Dra. Kozma s\u2019ha incorporat recentment a l\u2019IDIBELL, juntament amb el Dr. George Thomas, que tamb\u00e9 ha participat en l\u2019estudi. Els investigadors, procedents de la Universitat de Cincinnati, han posat en marxa un nou grup de Metabolisme i C\u00e0ncer al centre de recerca de Bellvitge.<\/p>\n
L\u2019estudi publicat a Science Translational Research ha estat realitzat a la Universitat de Cincinnati, en col\u00b7laboraci\u00f3 amb el Center for Cancer Research del National Cancer Institute dels Estats Units, la facultat de Medicina de la Universitat de California de Los Angeles, el Cincinnati Children\u2019s Hospital Medical Center i els instituts de recerca de Novartis.<\/p>\n
<\/p>\n
<\/p>\n
Hala Elnakat Thomas, Carol A. Mercer, Larissa S. Carnevalli,, Jongsun Park, Jesper B. Andersen, Elizabeth A. Conner, Kazuhiro Tanaka, Tomoo Matsutani, Akio Iwanami, Bruce J. Aronow, Liu Manway, S. Michel Maira, Snorri S. Thorgeirsson, Paul S. Mischel, George Thomas* and Sara C. Kozma*. mTOR Inhibitors Synergize Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma<\/strong>. Sci. Transl. Med. April 25 2012 [Epub ahead of print] DOI: 10.1126\/scitranslmed.3003923 La combinaci\u00f3 de dos inhibidors de la prote\u00efna mTOR aconsegueix frenar el creixement del c\u00e0ncer de fetge primari i destruir les c\u00e8l\u00b7lules tumorals, segons un estudi realitzat per investigadors del grup de Metabolisme i C\u00e0ncer de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL). Els resultats de l\u2019estudi s\u2019avancen en l\u2019edici\u00f3 digital de la revista Science Translational […]<\/p>\n","protected":false},"author":6,"featured_media":22108,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,408,447],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-08 05:39:00","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9516"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=9516"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9516\/revisions"}],"predecessor-version":[{"id":22109,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9516\/revisions\/22109"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22108"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=9516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=9516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=9516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n*Investigadors de l\u2019IDIBELL<\/p>\n","protected":false},"excerpt":{"rendered":"